HOS

HOS/HOS细胞系/HOS细胞株/HOS人骨肉瘤细胞

Cell line name HOS

Accession CVCL_0312

Resource Identification Initiative To cite this cell line use: HOS (RRID:CVCL_0312)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Population: Caucasian.

Doubling time: ~36 hours (PubMed=21519327).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: H3K4me1 ChIP-seq epigenome analysis.

Omics: H3K27ac ChIP-seq epigenome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.

PubMed=2463881; DOI=10.1093/carcin/10.2.265

Babich M.A., Day R.S. 3rd

Synergistic killing of virus-transformed human cells with interferon and N-methyl-N'-nitro-N-nitrosoguanidine.

Carcinogenesis 10:265-268(1989)

 

PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990; PMCID=PMC361354

Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.

p53 functions as a cell cycle control protein in osteosarcomas.

Mol. Cell. Biol. 10:5772-5781(1990)

 

PubMed=1385192; DOI=10.1016/0531-5565(92)90007-m

Fleming T.P., Matsui T., Aaronson S.A.

Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy.

Exp. Gerontol. 27:523-532(1992)

 

PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4

Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.

Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.

Cancer Genet. Cytogenet. 140:145-152(2003)

 

PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809

Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.

Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.

Cancer Res. 64:3395-3405(2004)

 

PubMed=15289353; DOI=10.1158/0008-5472.CAN-04-0522

Tsukahara T., Nabeta Y., Kawaguchi S., Ikeda H., Sato Y., Shimozawa K., Ida K., Asanuma H., Hirohashi Y., Torigoe T., Hiraga H., Nagoya S., Wada T., Yamashita T., Sato N.

Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor.

Cancer Res. 64:5442-5448(2004)

 

PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003

Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J., Squire J.A., Zielenska M.

Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization.

Cancer Genet. Cytogenet. 179:52-61(2007)

 

PubMed=19787792; DOI=10.1002/gcc.20717

Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.

Genes Chromosomes Cancer 49:40-51(2010)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=21519327; DOI=10.1038/labinvest.2011.72

Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.

Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.

Lab. Invest. 91:1195-1205(2011)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)